| Literature DB >> 24720782 |
Anne-Sofie Helvik1, Knut Engedal, Jūratė Saltytė Benth, Geir Selbæk.
Abstract
BACKGROUND: Few have studied how personal activities of daily living (P-ADL) develop over time in nursing home residents with dementia. Thus, the aim was to study variables associated with the development of P-ADL functioning over a 52-month follow-up period, with a particular focus on the importance of the degree of dementia.Entities:
Mesh:
Year: 2014 PMID: 24720782 PMCID: PMC3985541 DOI: 10.1186/1471-2318-14-45
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Characteristics of study sample at baseline (N=932)
| Previous length of stay (days) | Mean | 928.9 | (910.1) |
| Women | N | 686 | (73.6) |
| Age (year) | Mean | 84.5 | (7.5) |
| Single as marital status | N | 714 | (79.4) |
| Ten years of school or less | N | 673 | (74.1) |
| | | | |
| Co-morbidity index1 | Mean | 1.8 | (1.3) |
| Severely impaired hearing | N | 126 | (13.6) |
| Severely impaired vision | N | 139 | (14.9) |
| | | | |
| CDR sum of boxes | Mean | 13.1 | (4.0) |
| | | | |
| Agitation | Mean | 6.5 | (8.2) |
| Psychosis | Mean | 3.2 | (5.4) |
| Affective | Mean | 3.7 | (5.4) |
| Apathy | Mean | 2.4 | (3.8) |
| | | | |
| Antipsychotics | N | 241 | (25.9) |
| Antidepressants | N | 364 | (39.1) |
| Anxiolytics | N | 221 | (23.7) |
| Sedatives | N | 245 | (26.3) |
| Antidementia | N | 126 | (13.5) |
CDR= Clinical Dementia Rating Scale.
1The co-morbidity index was calculated by summing up the occurrence of diagnoses (yes/no) in nine groups of diagnoses.
2The cumulative proportion of psychotropic medication is higher than 100 due to combinational use of psychotropic medication.
Figure 1Flow chart of participants from baseline (T ) to last follow-up up (T ), with mean (SD) follow-up time at each assessment.
P-ADL score at four time points
| T1 | 6, 29 | 18.8 (5.3) |
| T2 | 7, 30 | 19.6 (5.2) |
| T3 | 7, 30 | 20.8 (4.8) |
| T4 | 9, 29 | 21.6 (4.6) |
Model 1: Effects of cognitive impairment (CDR sum of boxes) measured at baseline on P-ADL level over time estimated by linear mixed model with random effects for intercepts and time
| | | | | |
| Time | 0.19 (0.15; 0.24) | 0.20 (0.16; 0.25) | ||
| Time* time | -0.001 (-0.001; -0.0005) | -0.001 (-0.002; -0.001) | ||
| CDR sum of boxes | 0.72 (0.65; 0.79) | 0.61 (0.53; 0.69) | ||
| Time* CDR sum of boxes | -0.004 (-0.007; -0.001) | -0.004 (-0.007; -0.001) | ||
| | | | | |
| Length of stay | 0.002 (0.001; 0.002) | 0.001 (0.001; 0.001) | ||
| | | | | |
| Age (years) | -0.02 (-0.06; 0.02) | 0.312 | -0.05 (-0.09; -0.01) | |
| Women | -0.33 (-1.03; 0.38) | 0.362 | -0.62 (-1.25; 0.01) | 0.054 |
| Single | -0.80 (-1.58; -0.03) | -0.72 (-1.41; -0.03) | ||
| Ten years of education or less | 0.46 (-0.25; 1.17) | 0.206 | 0.48 (-0.12; 1.07) | 0.117 |
| | | | | |
| Co-morbidity index | 0.21 (-0.04; 0.46) | 0.100 | 0.32 (0.11; 0.53) | |
| No severe vision impairment | 1.65 (0.77; 2.53) | 0.93 (0.19; 1.67) | ||
| No severe hearing impairment | -0.79 (-1.70; 0.13) | 0.091 | -0.12 (-0.90; 0.66) | 0.765 |
| | | | | |
| Agitation sub-syndrome | 0.08 (0.04; 0.12) | 0.01 (-0.0; 0.04) | 0.546 | |
| Psychosis sub- syndrome | 0.04 (-0.02; 0.10) | 0.150 | | |
| Affective sub-syndrome | 0.02 (-0.04; 0.07) | 0.602 | | |
| Apathy | 0.35 (0.27; 0.43) | 0.10 (0.03; 0.18) | ||
| | | | | |
| Antipsychotics | 0.72 (0.01; 1.42) | -0.08 (-0.69; 0.53) | 0.802 | |
| Antidepressants | -0.56 (-1.19; 0.07) | 0.081 | -0.33 (-0.86; 0.20) | 0.225 |
| Anxiolytics | -0.28 (-1.01; 0.44) | 0.443 | -0.70 (-1.31; -0.10) | |
| Sedatives | -0.65 (-1.36; 0.05) | 0.070 | -0.12 (-0.70; 0.47) | 0.701 |
| Cognitive enhancers | -3.23 (-4.09; -2.36) | -1.81 (-2.58; -1.05) | ||
1The coefficients of the main effect variables (time, squared time, CDR sum of boxes, and interaction between time and CDR sum of boxes) unadjusted for other independent variables.
2The coefficients (95%CI) for single independent variables from the model containing only linear and second-order time components.
* = Multiplied with Bold data indicate p-value <0.05.
Model 2: Effects of cognitive impairment (CDR sum of boxes) measured at four time points on P-ADL level at the same time points estimated by linear mixed model with random effects for intercepts and time
| | ||||
|---|---|---|---|---|
| | | | | |
| Time | 0.06 (0.02; 0.10) | 0.18 (0.14; 0.22) | ||
| Time* time | 0.001 (-0.001; -0.001) | -0.001 (-0.001; -0.0004) | ||
| CDR sum of boxes (at 4 time points) | 0.48 (0.43; 0.54) | 0.60 (0.52; 0.67) | ||
| Time* CDR sum of boxes | 0.003 (0.001; 0.006) | -0.003 (-0.006; -0.0006) | ||
| | | | | |
| Length of stay | 0.002 (0.001; 0.002) | 0.001 (0.001; 0.0011) | ||
| | | | | |
| Age (years) | -0.02 (-0.06; 0.02) | 0.312 | -0.04 (-0.08; -0.004) | |
| Women | -0.33 (-1.03; 0.38) | 0.362 | -0.51 (-1.13; 0.11) | 0.108 |
| Single | -0.80 (-1.58; -0.03) | -0.78 (-1.45; -0.11) | ||
| Ten years of education or less | 0.46 (-0.25; 1.17) | 0.206 | 0.45 (-0.14; 1.03) | 0.136 |
| | | | | |
| Co-morbidity index | 0.21 (-0.04; 0.46) | 0.100 | 0.35 (0.15; 0.56) | |
| No severe vision impairment | 1.65 (0.77; 2.53) | 0.88 (0.14; 1.61) | ||
| No severe hearing impairment | -0.79 (-1.70; 0.13) | 0.091 | -0.16 (-0.92; 0.61) | 0.689 |
| | | | | |
| | | | | |
| Agitation sub-syndrome | 0.04 (0.02; 0.06) | 0.03 (0.003; 0.05) | ||
| Psychosis sub- syndrome | 0.02 (-0.01; 0.06) | 0.173 | | |
| Affective sub-syndrome | 0.01 (-0.03; 0.04) | 0.614 | -0.03 (-0.06; 0.01) | 0.166 |
| Apathy | 0.20 (0.15; 0.24) | 0.12 (0.08; 0.17) | ||
| | | | | |
| Antipsychotics | 0.77 (0.31; 1.23) | 0.41 (-0.03; 0.86) | 0.067 | |
| Antidepressants | -0.63 (-1.05; -0.20) | -0.40 (-0.80; 0.003) | 0.052 | |
| Anxiolytics | -0.67 (-1.15; -0.20) | -0.77 (-1.22; -0.32) | ||
| Sedatives | -0.29 (-0.75; 0.17) | 0.213 | | |
| Cognitive enhancers | -2.31 (-2.94; -1.67) | -1.72 (-2.33; -1.11) | ||
1The coefficients of the main effect variables (time, squared time, CDR sum of boxes, and interaction between time and CDR sum of boxes) unadjusted for other independent variables.
2The coefficients (95%CI) for single independent variables from the model containing only linear and second-order time components.
* = Multiplied with Bold data indicate p-value <0.05.
Figure 2Development of P-ADL score in time, unadjusted, adjusted in Model 1 and adjusted in Model 2. P-ADL values demonstrate a significant second-order time trend indicating that the P-ADL functioning declines at the start of the follow-up period and flattens out later. Adjustment of time trend for clinical and demographic characteristics resulted only in minor changes.